Lupin
Last updated Jul 6, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
68%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Respiratory
- Bronchodilator
- Gastroenterology
- H2 Antagonist
- Women's Health
Highest priority development: FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 68%
Active Signals
10
Investigate Priority
0
Opportunity Score
660
Buyer Quality
4 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 6, 2026Score 69Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
Oncology · Immunomodulator
- MonitorJul 11, 2026Score 67Lupin's Glycerol Phenylbutyrate Receives FDA Approval Status
Metabolic Disorders · Urea Cycle Disorder
- MonitorJul 14, 2026Score 66Lupin's Famotidine ANDA217432 Receives Abbreviated Approval from FDA
Gastroenterology · H2 Antagonist
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Wild Arabic Herbs - 729192 - 06/17/2026Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA TA — ANDA218552Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Lupin right now?
- Which regulatory precedents should Lupin monitor in Respiratory and Bronchodilator?
- Which pipeline programs should Lupin prioritize for competitive review?
- What signals require immediate investigation for Lupin?
- Summarize the strategic implications of recent developments for Lupin.
- Where is the greatest uncertainty in Lupin's competitive positioning?